Main Article Content
Objectives. In this study the in vitro activity of tigecycline, member of a new class of antimicrobial agents, the glycylcyclines, was evaluated against clinical isolates collected in Italy. Study Design. A total of 313 clinical pathogens were collected and identified in our Institution during 2007-2008. Minimum inhibitory concentrations (MICs) of the antimicrobial agents were determined by the CLSI (2007) recommended broth microdilution method. Results. Globally 205 Gram-negative and 108 Gram-positive pathogens were evaluated.Tigecycline demonstrated excellent inhibitory activity against Acinetobacter spp., H. influenzae, E. coli, Enterococcus spp., S. aureus, S. agalactiae and S. pneumoniae with MIC90 ≤1mg/l. Conclusion. Tigecycline exhibited potent in vitro antibacterial activity (comparable to or greater than most commonly employed antimicrobials) against both Gram-positive and negative clinical pathogens.These data suggest that tigecycline, with an expanded broad-spectrum antimicrobial activity, may be an effective empiric therapeutic option for the treatment of serious infections caused by clinically relevant pathogens.
Downloads month by month
Download data is not yet available.